Partnering to advance groundbreaking programs in precision oncology
We are committed to partnering with the best and brightness minds in academia, biotechnology and pharma to advance programs in targeted/precision oncology. We partner with teams that share our vision to advance promising programs in potentially lethal diseases where the unmet need remains frustratingly high.
We are actively seeking opportunities to collaborate in any of the following areas:
Precision oncology programs across solid tumors
Neuro-oncology programs that select for genetically defined tumors
Novel mechanisms of action; either first-in-class or potentially best-in-class
Both pre-clinical and clinical stage assets
The management team at Chimerix has substantial experience in oncology drug development, manufacturing scale up and global regulatory expertise to accelerate precision oncology programs to approval. For more information about how we might work together, please contact Tom Riga, COO and CCO, at [email protected].
Key benefits of collaborating with Chimerix include:
Strong culture of execution
Extensive clinical development and regulatory experience
Creativity in constructing partnerships
Commitment to professional alliance management
Track record of pioneering novel therapeutic targets for molecularly-defined diseases
Tom Riga, Chief Operating Officer & Chief Commercial Officer
“At Chimerix, our goal is to have a profound impact on cancer patients who have a high unmet medical need. Establishing productive partnerships with collaborators across the globe is a key driver in finding the right innovation to fight this elusive and complex disease. We have a long history of diverse partnerships across large pharmaceutical companies, smaller biotechs, geographic partnerships, government agencies and academic research institutions. Our approach to these relationships is guided by simple, yet direct principles: we invest wisely, operate with high integrity, impart a sense of urgency and are honest about where the data lead us.”
